Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment ...

Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD ® - Lenalidomide capsules, referencing REVLIMID ® BRIDGEWATER, N.J., February 19, 2025--(BUSINESS WIRE)--Amnea ...

(Nasdaq: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for ...

As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation ("Twist" or the "Company"), a core mid-cap growth and value equity company in the life sciences segment of the health ...

Mesalamine, a complex aminosalicylate medication, has a limited number of suppliers, underlining Amneal's R&D capabilities. The FDA-approved lenalidomide, a thalidomide analogue, is indicated for ...

Mesalamine, a complex aminosalicylate medication, has a limited number of suppliers, underlining Amneal's R&D capabilities. The FDA-approved lenalidomide, a thalidomide analogue, is indicated for ...